On March 25, 2026, BiomX Inc. received formal notification that it failed to meet NYSE American continued listing requirements under Sections 1003(a)(i), (ii) and (iii), which mandate minimum stockholders’ equity of $2 million, $4 million and $6 million respectively after net losses. The notice confirmed no current exemption applies, including market capitalization relief.

BiomX must submit a detailed plan by April 24, 2026 outlining the measures it will take to restore required equity levels by September 25, 2027. If the plan is accepted, the company will undergo quarterly reviews; failure to file, gain acceptance or make sufficient progress will trigger delisting proceedings with rights of appeal under the listing rules.

BiomX’s independent auditor included an explanatory paragraph in the 2025 audit report expressing substantial doubt about the company’s ability to continue as a going concern. This qualification underscores the importance of securing additional financing or improving operational results to address ongoing liquidity challenges.